翻译Abdominal aortic aneurysm is a common disease that particularly affects men older than…
- User
翻译Abdominal aortic aneurysm is a common disease that particularly affects men older than 60 years. As the size of the aneurysm increases the risk of rupture increases. Since 1951, surgical repair has been practised.1 Minimally invasive vascular repair was first reported in 1986.2 Three principal, randomised controlled trials3, 4, 5 for abdominal aortic aneurysm have shown marked benefits of endovascular aneurysm repair (EVAR) with respect to 30-day mortality. However, the total mortality benefit was lost (catch-up of mortality) in these randomised controlled trials after 2 years (in the UK Endovascular Aneurysm Repair trial 1 [EVAR trial 1]),6 1–2 years (DREAM),7 and 5 years (OVER).8
- Assistant
腹主动脉瘤是一种常见疾病,特别是在60岁以上的男性中更为普遍。随着瘤体大小的增加,瘤体破裂的风险也随之升高。自1951年以来,外科修复手术已被实践。1986年首次报道了微创血管修复手术。针对腹主动脉瘤,三项主要的、随机对照试验显示了腹内膜瘤修复术(EVAR)在30天内死亡率方面的显著好处。然而,这些随机对照试验在2年后失去了总体死亡率方面的好处(在英国腹内膜瘤修复试验1(EVAR试验1)中出现死亡率的追平),在1-2年后(DREAM试验),以及5年后(OVER试验)。
- User
翻译为中文论文语言Abdominal aortic aneurysm (AAA) is a multifactorial disease and a potentially lifethreatening condition. Pharmacological approaches to slow aneurysm progression and limit the near-fatal risk of acute ruptures are currently under investigation to reduce the negative impact on the healthcare system
- Assistant
腹主动脉瘤(AAA)是一种多因素疾病且潜在生命威胁性状况。为了减轻对医疗系统的负面影响,目前正在研究药物方法来减缓瘤体进展和限制急性破裂的近致命风险。
- User
翻译为中文论文语言Endovascular aortic aneurysm repair (EVAR) has now become the standard of care which has been shown to reduce morbidity and mortality [2]. However, short-term and long-term complications still hamper procedural success, and the most common complication is the residual perfusion of the aneurysmal sac (i.e., endoleak). Considering their frequency, patients undergo long-term surveillance screening with computed tomographic angiography or vascular ultrasound, which are limited by contrast administration or poor accuracy, respectively. Post-procedural complications and their assessment might impact the cost-effectiveness of EVAR.
- Assistant
内膜瘤修复术(EVAR)现已成为降低发病率和死亡率的标准治疗方法。然而,短期和长期并发症仍然阻碍着手术的成功,最常见的并发症是瘤囊残余灌注(即内漏)。考虑到它们的频发性,患者需要进行长期的监测筛查,使用计算机断层血管造影或血管超声检查,但这些方法分别受限于对比剂的使用或精确度的不足。术后并发症及其评估可能会影响EVAR的成本效益。
- User
翻译Therefore, the study of circulating biomarkers has been progressively introduced in the medical literature and in the near future, these biomarkers might help in identifying conditions prone to develop complications, for both post-EVAR patients and patients with aortic aneurysm in follow up. This review will discuss the current biomarkers in the setting of AAA, with particular emphasis on patients undergoing EVAR.
- Assistant
因此,循环生物标志物的研究已逐步引入医学文献,并且在不久的将来,这些生物标志物可能有助于识别易于发展并发症的状况,包括接受EVAR治疗的患者以及随访中的主动脉瘤患者。本篇综述将讨论在AAA背景下的当前生物标志物,特别强调接受EVAR治疗的患者。
- User
翻译为中文论文语言Abdominal aortic aneurysm (AAA) is a multifactorial disease and a potentially life-threatening condition. Pharmacological approaches to slow aneurysm progression and limit the near-fatal risk of acute ruptures are currently under investigation to reduce the negative impact on the healthcare system [1]. Endovascular aortic aneurysm repair (EVAR) has now become the standard of care which has been shown to reduce morbidity and mortality [2]. However, short-term and long-term complications still hamper procedural success, and the most common complication is the residual perfusion of the aneurysmal sac (i.e., endoleak). Considering their frequency, patients undergo long-term surveillance screening with computed tomographic angiography or vascular ultrasound, which are limited by contrast administration or poor accuracy, respectively. Post-procedural complications and their assessment might impact the cost-effectiveness of EVAR.
- Assistant
腹主动脉瘤(AAA)是一种多因素疾病,且可能威胁生命。目前正在研究药物治疗方法,以减缓瘤体进展和降低急性破裂的近致命风险,以减少对医疗系统的负面影响。内膜瘤修复术(EVAR)现已成为降低发病率和死亡率的标准治疗方式。然而,短期和长期并发症仍妨碍手术成功,其中最常见的并发症为瘤囊的残余灌注(即内漏)。考虑到这些并发症的发生频率,患者需要接受长期的监测筛查,采用计算机断层血管造影或血管超声检查,但分别受限于对比剂的使用和精度不高。术后并发症及其评估可能会影响EVAR的成本效益。
- User
翻译The goal of endovascular aortic repair (EVAR) is to exclude the aneurysm. However, it is not uncommon that blood flow persists within the aneurysm sac after EVAR—a phenomenon called endoleak. Although there is consensus about how to manage endoleak types I and III, what constitutes the best course of action for type 2 endoleak remains controversial
- Assistant
内膜瘤修复术(EVAR)的目标是排除主动脉瘤。然而,EVAR后瘤囊内仍有血流持续存在——这种现象称为内漏,并不罕见。尽管对于如何管理内漏类型I和类型III有共识,但对于最佳处理类型2内漏的做法仍然存在争议。